Crucell N.V.
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
28 sep 2007 - 08:25
Statutory name
Crucell N.V.
Title
Crucell discovers human monoclonal antibodies for the prevention and treatment of the avian flu virus. The antibody provides immediate protection and neutralizes the broadest range of H5N1 strains.
Comments
Leiden, The Netherlands, September 27, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced the discovery of a set of human monoclonal antibodies against H5N1.
Related downloads
Date last update: 22 June 2026